9月22日上午，南京建邺区迎来了一场具有里程碑意义的盛会——由华检医疗（01931）主办的"全球首个RWA技术基地落成仪式"在此召开。 这座被命名为ETHK大厦（即华检医疗大厦）的建筑，不仅是华检医疗倾力打造的物理空间，更是全球现实世界资产（RWA）数字化技术研发与生态赋能的 核心基地。它的正式启用，标志着华检医疗"ETHK链上金融生态战略"迈入实体化、规模化技术落地的新纪元，也意味着南京正崛起为RWA技术的全球超级 枢纽。 一、技术落地新纪元：RWA赛道的"南京枢纽" RWA（Real World Asset）即现实世界资产代币化，正成为全球金融科技最炙手可热的领域。据香港Web3.0标准化协会报告，RWA产业正处于从概念验证向 规模化应用转型的关键节点，Defillama数据显示，截至2025年6月，RWA总锁仓量（TVL）达125亿美元，较2024年增长124%。 通过设立ETHK Inc.和ETHK HOLDINGS LIMITED两家合资公司，并计划更名为"ETHK Labs Inc."，华检医疗已经明确转型为数字产业基础设施提供者。此 次ETHK大厦的落成，是其技术战略的实体化宣言。 大厦坐落南京 ...

Group 1 - The establishment of the ETHK building marks a significant milestone for the company, representing the physical realization of its ETHK blockchain financial ecosystem strategy and positioning Nanjing as a global hub for Real World Asset (RWA) technology [1][4][14] - The RWA sector is transitioning from concept validation to large-scale application, with a projected total value locked (TVL) of $12.5 billion by June 2025, reflecting a 124% increase from 2024 [4] - The ETHK building will serve as a core base for RWA digital technology research and ecosystem empowerment, housing over 5,000 technical experts and various research facilities [7][14] Group 2 - The company has signed strategic cooperation agreements with four enterprises, including a $1.5 billion RWA tokenization deal with Chuangsheng Group, integrating six core innovative drug pipeline assets into its U.S. entity [8][13] - The partnerships aim to create a comprehensive ecosystem from biopharmaceutical innovation to legal compliance, enhancing the efficiency of asset value discovery and circulation through digitalization [13][14] - The company's "so-in-so" model aims to build a top-tier global trading ecosystem for RWA across multiple industries, providing a one-stop solution for asset digital transformation [13][14] Group 3 - The launch of the ETHK building and the strategic partnerships signify the company's transition into a scalable phase of its ETHK blockchain financial ecosystem strategy [14][15] - The RWA tokenization path chosen by the company is seen as forward-looking, with predictions estimating the global RWA market to reach $16.1 trillion by 2030, accounting for 10% of global GDP [15] - The company's "altruistic" approach allows partners to optimize their asset structures and innovate financing models, facilitating the development of cutting-edge therapies and improving patient accessibility [15][16]